CN107278229A - 用于治疗胰岛素抵抗的靶向转录因子tsc22d4的寡核苷酸序列 - Google Patents

用于治疗胰岛素抵抗的靶向转录因子tsc22d4的寡核苷酸序列 Download PDF

Info

Publication number
CN107278229A
CN107278229A CN201680012500.4A CN201680012500A CN107278229A CN 107278229 A CN107278229 A CN 107278229A CN 201680012500 A CN201680012500 A CN 201680012500A CN 107278229 A CN107278229 A CN 107278229A
Authority
CN
China
Prior art keywords
administration
inhibitor
tsc22d4
insulin resistance
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680012500.4A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·赫兹格
莫里希奥·贝里尔迪亚兹
托拜厄斯·斯查弗梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of CN107278229A publication Critical patent/CN107278229A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680012500.4A 2015-03-23 2016-02-12 用于治疗胰岛素抵抗的靶向转录因子tsc22d4的寡核苷酸序列 Pending CN107278229A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15160259.6A EP3072969A1 (en) 2015-03-23 2015-03-23 Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
EP15160259.6 2015-03-23
PCT/EP2016/053050 WO2016150618A1 (en) 2015-03-23 2016-02-12 Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
CN107278229A true CN107278229A (zh) 2017-10-20

Family

ID=52784935

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680012500.4A Pending CN107278229A (zh) 2015-03-23 2016-02-12 用于治疗胰岛素抵抗的靶向转录因子tsc22d4的寡核苷酸序列

Country Status (11)

Country Link
US (2) US10676739B2 (https=)
EP (2) EP3072969A1 (https=)
JP (1) JP2018513841A (https=)
KR (1) KR20170128348A (https=)
CN (1) CN107278229A (https=)
BR (1) BR112017016021A2 (https=)
DK (1) DK3274455T3 (https=)
ES (1) ES2837085T3 (https=)
MX (1) MX384193B (https=)
RU (1) RU2723091C2 (https=)
WO (1) WO2016150618A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7289510B2 (ja) * 2019-05-08 2023-06-12 国立大学法人高知大学 認知症治療薬のスクリーニング方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014202602A1 (en) * 2013-06-17 2014-12-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of insulin resistance through inhibitors of transcription factor tsc22d4

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503313A (ja) * 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
WO2012158123A1 (en) 2011-05-13 2012-11-22 Agency For Science, Technology And Research Compounds and methods for treating insulin resistance syndrome
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
RU2573450C1 (ru) * 2014-08-11 2016-01-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ выявления генов-мишеней для диагностики и терапии лейкозов человека

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014202602A1 (en) * 2013-06-17 2014-12-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of insulin resistance through inhibitors of transcription factor tsc22d4

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENBANK ACCESSION NO：NM_023910.6: "Mus musculus TSC22 domain family, member 4 (Tsc22d4), transcript variant 2, mRNA", 《GENBANK》 *
GENBANK ACCESSION NO：NM_030935.3: "Homo sapiens TSC22 domain family, member 4 (TSC22D4), mRNA", 《GENBANK》 *
LAGANÀ ALESSANDRO等: "Computational Design of Artificial RNA Molecules for Gene Regulation", 《METHODS IN MOLECULAR BIOLOGY》 *

Also Published As

Publication number Publication date
MX384193B (es) 2025-03-12
EP3274455B1 (en) 2020-10-14
RU2017131900A (ru) 2019-04-23
RU2017131900A3 (https=) 2019-06-10
KR20170128348A (ko) 2017-11-22
WO2016150618A1 (en) 2016-09-29
EP3274455A1 (en) 2018-01-31
US11053499B2 (en) 2021-07-06
US10676739B2 (en) 2020-06-09
RU2723091C2 (ru) 2020-06-08
CA2979115A1 (en) 2016-09-29
MX2017012231A (es) 2018-01-30
JP2018513841A (ja) 2018-05-31
ES2837085T3 (es) 2021-06-29
US20180023078A1 (en) 2018-01-25
EP3072969A1 (en) 2016-09-28
US20200255834A1 (en) 2020-08-13
DK3274455T3 (da) 2020-12-14
BR112017016021A2 (pt) 2018-03-20

Similar Documents

Publication Publication Date Title
EP1799826B1 (en) siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN
DK2217704T3 (en) Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis
EA033653B1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
TW201136594A (en) Modulation of hsp47 expression
US20100086526A1 (en) Nucleic acid constructs and methods for specific silencing of h19
EP2283846A1 (en) miRNA compounds for treatment of prostate carcinoma
US20090023670A1 (en) Regulation of Transgene Expression by RNA Interference
WO2012094115A1 (en) Compositions and methods for inhibiting expression of flt3 genes
US11053499B2 (en) Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
WO2011054939A2 (en) Compositions and methods for inhibiting expression of kif10 genes
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
JP2022530031A (ja) ｍｉＲ－１０模倣体およびその標的に関する方法および組成物
CA2979115C (en) Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance
JPWO2010079819A1 (ja) 肥満または糖尿病治療用医薬組成物
WO2019052000A1 (zh) 一种靶向STAT3信号通路miRNA及其制备方法和应用
JPWO2005010185A1 (ja) Ｋｌｆ５遺伝子の発現を抑制するｒｎａ
KR100930282B1 (ko) ＮＩＫ 유전자에 대한 ｓｉＲＮＡ 및 이를 포함하는 간질환치료제
CN101173275B (zh) 抑制sars冠状病毒m蛋白基因表达的小干扰rna及其编码基因与应用
RU2575056C2 (ru) Модуляция экспрессии hsp47
CN102427852A (zh) 用于抑制糖皮质素受体(gcr)基因表达的组合物和方法
WO2019036871A1 (zh) 特异敲低人miR-148a、miR-185和miR-424表达的Tud RNA及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination